New Life for Venue Challenges under TC Heartland after Rule 12 Motions Are Concluded

May 25, 2017

Reading Time : 2 min

TC Heartland upended 30 years of Federal Circuit precedent concerning proper venue for corporate defendants in patent infringement cases. The patent venue statute provides that venue is proper in any judicial district in which the defendant “resides” or where “the defendant has committed acts of infringement and has a regular and established place of business.” 28 U.S.C. § 1400(b). Prior to TC Heartland, the term “resides” was defined in accordance with the definition of residency in the general venue statute, which provides that “a corporation shall be deemed to reside in any judicial district in which it is subject to personal jurisdiction at the time the action is commenced.” 28 U.S.C. § 1391(c). Thus, under the old standard, a plaintiff could establish proper venue for a corporate defendant simply by establishing personal jurisdiction.

In TC Heartland, the Supreme Court held that the term “resides” in § 1400(b) refers to only the state of incorporation for domestic corporations. TC Heartland, 2017 U.S. LEXIS 3213, at *17. Therefore, to establish venue for a domestic corporation under the new standard, a plaintiff must demonstrate that the defendant is incorporated in the state within which the district sits or that “the defendant has committed acts of infringement and has a regular and established place of business.” See §1400(b) (emphasis added); see also TC Heartland, 2017 U.S. LEXIS 3213, at *10, 17.

TC Heartland opens the door for defendants to raise improper venue defenses in cases filed outside their home states and where they do not maintain a “regular and established place of business.” But, in many active cases, plaintiffs may argue that despite the change resulting from the Supreme Court’s decision, the rules do not permit a venue challenge. Such an argument ignores the limits of the waiver rule and also the courts’ inherent authority to manage their dockets and exercise discretion in permitting challenges based on changed law or circumstances. Under Rule 12 of the Federal Rules of Civil Procedure, certain defenses—including improper venue—may be waived if they are not raised in a Rule 12 motion or responsive pleading. See Fed. R. Civ. P. 12(h)(1). But, such defenses are only susceptible to a waiver argument if they were “available” at the time of the motion or responsive pleading. See Fed. R. Civ. P. 12(g)(2).

The Court’s decision to order both parties to brief the venue issue supports either that the Court believes that these circumstances fall outside the waiver provision of Rule 12 or that a venue challenge at this time is warranted in any event due to the significance of the Supreme Court's decision (or that such briefing is appropriate on both grounds). Although the Court did not recite its rationale in the Text Order, this case signals an important consideration for defendants sued outside of their home courts, regardless of the stage of the case and proximity to the initial pleadings.

Columbia Insurance Co. et al v. Integrated Stealth Technology Inc., 3-16-cv-03091 (ILCD May 23, 2017, Order) (Myerscough, USDJ)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.